Ann: Presentation to Investors, page-6

I note with interest the careful wording here in this BIT investor presentation 

NOTE THAT THE VERBIAGE IN REGARD TO THE RECENT EUPHORIA AROUND THE HIV-1 PHASE 2 TRIAL REFERS TO IT AS "POSITIVE NEWS" NOT POSITIVE DATA - this distinction should not be lost on those more educated in this space.

Lead candidate BIT225 is a novel, first-in-class, oral small molecule drug

• In development for treatment of HIV-1 and Hepatitis C virus (HCV)

• Positive data in trials to date

• Recently reported positive news from the HIV-1 Phase 2 trial